Conference Presentations

2017 (Apr., 2017~ Mar.,2018)

Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer

Norikazu Masuda, Nobuaki Sato, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.12 SABCS poster San Antonio, USA

Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)

Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, Katsumasa Kuroi, Hiroyuki Yasojima, Hiroi Kasai, Tsuyoshi Takasuka, Takaki Sakurai, Tatsuki R. Kataoka, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.9 ESMO Poster Madrid

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer: A subgroup analysis (JBCRG-C06)

Kenjiro Aogi, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano Eriko Tokunaga, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
2017.9 ESMO Poster Madrid

Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03)

Kazutaka Narui, Toshinari Yamashita, Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.06 ASCO Poster Chicago

2016 (Apr., 2016~ Mar.,2017)

Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (The JBCRG-M01 study)

Shigehira Saji, Hiroshi ishiguro, Shogo Nomura, Hiroji Iwata, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi, Japan Breast Cancer Research Group
2016.10 ESMO Poster Copenhagen

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH

Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Oogami Masahiro, Honma Masato, Satoru Shimizu, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoshi Morita, Masakazu Toi
2016.12 SABCS Poster San Antonio, Texas

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).

Naoto Kondo, Yoshinori Ito, Ippei Fukada, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda
2016 ASCO Poster

PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy (JBCRG-M05).

Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, Fumitaka Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno.
2016 ASCO Poster

Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16)

Kosuke Kawaguchi, Eiji Suzuki, Tatsuki R Kataoka, Masahiro Hirata, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Japan Breast Cancer Research Group (JBCRG)
2016 ASCO Poster

2015 (Apr., 2015~ Mar.,2016)

Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

Naoto Kondo, Yutaka Yamamoto, Hiroyasu Yamashiro, Masahiro Kashiwaba, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno
2016 EBCC Poster

Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)

Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji,Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Shinji Ohno, Masakazu Toi
2016 EBCC Poster

Pharmacogenomics-pharmacokinetics study of selective estrogen-receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients (JBCRG-12,15)

Shinji Ohno, Hiroshi Ishiguro, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi
2015 SABCS Poster

CREATE-X (JBCRG-04): A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X , JBCRG-04)

Soo-Jung Lee, Masakazu Toi, Eun Sook Lee, Shoichiro Ohtani, Young-Hyuck Im, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shintaro Takao, Shinji Ohno, Kenjiro Aogi, Hiroji Iwata, Aeree Kim, Hironobu Sasano, Isao Yokota, Yasuo Ohashi, Norikazu Masuda
2015 SABCS Oral

Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients (pts)

Hiroko Bando, Norikazu Masuda, Rikiya Nakamura, Naoto Kondo, Katsumasa Kuroi, Mayumi Ishida, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Yasuhiro Yanagita, Hiroshi Ishiguro, Satoru Shimizu, Kenjiro Aogi, Sadao Amano, Shinji Ozaki, Akiko Iguchi-Manaka, Hiroi Kasai, Satoshi Morita, Tastuki R. Kataoka, Masakazu Toi
2015 ECCO Poster

Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy

Toshinari Yamashita, Norikazu Masuda, Naohito Yamamoto, Naoto Kondo, Hiroko Bando, Sayuri Akiyoshi, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Tomomi Fujisawa, Hiroshi Ishiguro, Hirotaka Nakayama, Kenjiro Aogi, Sadao Amano, Shinji Ozaki, Hiroyuki Yasojima, Hiroi Kasai, Tastuki R. Kataoka, Satoshi Morita, Masakazu Toi
2015 ECCO Poster

Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer (JBCRG-C06:Safari)

Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Yutaka Yamamoto, Shigehira Saji, Shoichiro Ohtani, Yoshie Hasegawa, Toshinari Yamashita, Satoshi Morita, Shinji Ohno
2015 Japanese Breast Cancer Society POSTER

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)

Norikazu Masuda, Ippei Fukada, Naoto kondo, Shoichiro Ohtani, Masaya Hattori, Taijiro Kosaka, Masahiko Tanabe, Kohjiro Mashino, Nobuki Matsunami, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Yasuaki Sagara, Katsumasa Kuroi, Shinji Ohno, Masakazu Toi, Yoshinori Ito
2015 Japanese Breast Cancer Society POSTER

Investigation of Dual-HER2 Blockage Therapy in HER2-Positive Breast Cancer (exploratory randomized P-II) (JBCRG-16 NeoLath)

Naohito Yamamoto, Norikazu Masuda, Naoto Kondo, Hiroko Bando, Katsumasa Kuroi, Shinji Ohno, Takeshi Miyamoto, Kenji Higaki, Toshimi Takano, Kenichi Inoue, Rikiya Nakamura, Satoru Shimizu, Hiroshi Ishiguro, Kenjiro Aogi, Sadao Amano, Hiroyasu Yamashiro, Hiroi Kasai, Satoshi Morita, Takaki Sakurai, Masakazu Toi
2015 Japanese Breast Cancer Society POSTER

2014 (Apr., 2014~ Mar.,2015)

Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer

Hiroji Iwata, Naohito Yamamoto, Norikazu Masuda, Hiroko Bando, Katsumasa Kuroi, Shinji Ohno, Hiroi Kasai, Satoshi Morita, Takaki Sakurai, Masakazu Toi
St.Gallen Poster

Bevacizumab plus Paclitaxel optimization study with interventional maintenance endocrine therapyin advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial, ASCO 2014

Shigehira Saji, Masakazu Toi, Takashi Ishikawa, Takanori Ishida, Shoichiro Ohtani, Masahiro Kashiwaba,Yasuaki Sagara, Shigenori Nagai, Yoshie Hasegawa, Tomomi Fujisawa, Norikazu Masuda, Koji Matsumoto,Yutaka Yamamoto, Hiroshi Yoshibayashi, Naruto Taira, Satoshi Morita, Shinji Ohno
2014 ASCO Poster (trial in progress)

Back to Page Top

2013 (Apr., 2013~ Mar.,2014)

Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04) PDF

Shoichiro Ohtani, Norikazu Masuda, Young-Hyuck Im, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shintaro Takao, Shinji Ohno, Kenjiro Aogi, Hiroji Iwata, Katsuhide Yoshidome, Reiki Nishimura, Eun Sook Lee, Isao Yokota, Yasuo Ohashi, Soo-Jung Lee, Masakazu Toi
2013 SABCS Poster

A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC, and TC-FEC as preoperative chemotherapy for hormone receptor-positive and HER2-negative primary breast cancer: Japan Breast Cancer Research Group (JBCRG) - 09

Nobuaki Sato, Norikazu Masuda, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka, and Masakazu Toi
2013 SABCS Poster

Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study) PDF

Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katsumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yasuhiro Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita, Masakazu Toi
2013 SABCS Poster

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (JBCRG-13) PDF

Kenji Higaki, Norikazu Masuda, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani,Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi
2013 ASCO Poster

Safety of trastuzumab in HER2 positive primary breast cancer in Japan; Initial safety report for the large scale cohort study (JBCRG-C01) PDF

N. Yamamoto, H. Yamashiro, H. Iwata, N. Masuda, S. ohtani, M. Takahashi, K. Yamazaki, M. Kato, S. Ohno, K. Kuroi, K. Yamagami, T. Morimoto, Y. Hasegawa, T. Takano, H. Shigematsu, M. Hosoda, H. Abe, S. Morita, S. Yasuno, M. Toi
2013 ASCO Poster

Cohort study evaluating trastuzumab in HER2 positive early breast cancer in Japan; JBCRG-C01

N. Masuda, H. Yamashiro, H. Iwata, R. Nishimura, N. Sato, T. Kamio, T. Saito, T. Lee, S. Yasuno, M. Toi
St Gallen 2013, 3

Back to Page Top

2012 (Apr., 2012~ Mar.,2013)

A Prospective Multicenter Randomized Phase II Neo-Adjuvant Study of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Docetaxel, Cyclophosphamide and Trastuzumab (TCH) Versus TCH Followed by FEC Versus TCH Alone, in Patients (pts) with Operable HER2 Positive Breast Cancer: JBCRG-10 Study PDF

Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M
34th San Antonio Breast Cancer Symposium, Poster Session, San Antonio(USA), Dec.2012

Inter-observer concordance of Ki-67 labeling index inbreast cancer[br]: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study

T Ueno, Y Mikami, K Yoshimura, H Tsuda, M Kurosumi, S Masuda, R Horii, M Toi, and H Sasano
34th San Antonio Breast Cancer Symposium, Poster Session, San Antonio(USA), Dec.2012

JBCRG 10 years footstep and vision

Katsumasa Kuroi
Hiroshima University Faculty of Medicine, Koujin kaikan 2F, Main Hall

Back to Page Top

2011 (Apr., 2011~ Mar.,2012)

A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): the efficacy and its correlation with circulating endothelial cells.

Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Sunao Tanaka, Masakazu Toi
2011 American Society of Clinical Oncology, Chicago (USA), Jun. 2011

Back to Page Top

2010 (Apr., 2010~ Mar.,2011)

Update HER2 Therapy for Breast Cancer

Dr. Jose Baselga, M.D., Ph.D.
33rd San Antonio Breast Cancer Symposium, Meet the Experts, San Antonio(USA), Dec.2010

Indication of adjuvant chest wall irradiation after mastectomy in Japan from the standpoint of the international collaborative study SUPREMO

Kuroi K, Masuda N, Aogi K, Iwata H, Ueno T, Ohno S, Kashiwaba M, Sato N, Nakamura S, Nakayama T, Toi M; Japan Breast Cancer Research Group (JBCRG)
The 18th Annual Meeting of the Japanese Breast Cancer Society, Sapporo, Jun 2010

The contrivance of success in the clinical trial and the prospect in the future on JBCRG

Masuda N, Aogi K, Iwata H, Ueno T, Ohno S, Kashiwaba M, Kuroi K, Sato N, Nakamura S, Nakayama T, Toi M; Japan Breast Cancer Research Group (JBCRG)
The 18th Annual Meeting of the Japanese Breast Cancer Society, Sapporo, Jun 2010

A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study).

N. Masuda, M. Toi, T.Ueno, K. Aogi, H. Iwata, S. Ohno, K. Kuroi, N. Sato, S. Nakamura; Japan Breast Cancer Research Group (JBCRG)
2010 American Society of Clinical Oncology, Chicago (USA), Jun. 2010

Back to Page Top

2009(Apr., 2009~ Mar.,2010)

Comparison of Molecular characterization of ER+early-stage cancer by standardized quantitative RT-PCR analysis between Japanese and North American populations.

Masuda N, Yamanaka T, Iwata H, Ohno S, Nakamura S, Kashiwaba M, Kamigaki S, Aogi K, Ueno T, Toi M; Japan Breast Cancer Research Group (JBCRG)
ASCO Breast, San Francisco, USA, Oct. 2009

View of new clinical trials for breast cancer patients considered from the results of preoperative systemic therapy on JBCRG

Masuda N, Aogi K, Iwata H, Ueno T, Ohno S, Kashiwaba M, Kuroi K, Sato N, Nakamura S, Nakayama T, Toi M; Japan Breast Cancer Research Group (JBCRG)
The 47th Annual Meeting of Japan Society of Clinical Oncology (Yokohama) Symposium16, 2009

Phase I/II study of irinotecan hydrochloride (CPT-11) combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)

Saji S, Ishiguro H, Iwata H, Nakamura S, Kuroi K, Ohno S, Masuda N, Yamanaka T, Sasaki Y, Inamoto S, Toi M; Japan Breast Cancer Research Group (JBCRG)
The 17th Annual Meeting of the Japanese Breast Cancer Society, Tokyo, Jul 2009

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey

K. Kawaguchi, H. Ishiguro, S. Morita, S. Nakamura, S. Ohno, N. Masuda, H. Iwata, K. Aogi, K. Kuroi, M. Toi; Japan Breast Cancer Research Group (JBCRG)
2009 American Society of Clinical Oncology, New Orleans (USA), Jun. 2009

The first report of the association between the recurrence score and risk of recurrence in Japanese population (JBCRG-TR03)

Toi M, Iwata H, Masuda N, Ohno S, Nakamura S, Yamanaka T, Nakayama T,Kashiwaba M, Kamigaki S, Aogi K, Ueno T, Kuroi K: Japan Breast Cancer Research Group (JBCRG)
Kyoto Breast Cancer Consensus Conference International Convention 2009, Kyoto, April 2009

Back to Page Top

2008(Apr., 2008~ Mar.,2009)

Significance of HER2/TOPO IIα analysis as a predictive factor of the therapeutic effect in preoperative chemotherapy (JBCRG-TR01)

Shinichiro Horiguchi, Katsumasa Kuroi, Masato Takahashi, Keiko Yamashita, Nobuaki Sato, Hiroji Iwata, Norikazu Masuda, Seigo Nakamura, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
The 16th Annual Meeting of the Japanese Breast Cancer Society, Osaka, Sep 2008

JBCRG03: Preoperative chemotherapy using Docetaxel 75 followed by FEC 100 as primary systemic chemotherapy for operable breast cancer

Naohito Yamamoto, Hiroji Iwata, Nobuaki Sato, Norikazu Masuda, Seigo Nakamura, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
The 16th annual meeting of the Japanese Breast Cancer Society, Symposium 2 ,Osaka, Sep. 2008

New system to promote translational researches using samples of clinical trials

Akemi Kataoka, Shinji Ohno, Masakazu Toi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Tatsuya Toyama, Norikazu Masuda, Eriko Tokunaga, Kazumi Horiguchi; Japan Breast Cancer Research Group (JBCRG)
The 108th Annual Congress of Japan Surgical Society, Nagasaki, May 2008

Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial

Sato N, Iwata H, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Toi M; Japan Breast Cancer Research Group (JBCRG)
6th European Breast Cancer Conference, Poster, Berlin (Germany), Apr. 2008

Back to Page Top

2007(Apr., 2007~ Mar.,2008)

JBCRG03:Preoperative chemotherapy using Docetaxel, followed by FEC 100 - Review of and breakthrough by JBCRG01 and 02 -

Masahiro Kashiwaba, Go Wakabayashi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Norikazu Masuda, Nobuaki Sato, Taro Asaga, Naohito Yamamoto, Kenjiro Aogi, Yasuyuki Sato, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
The 15th annual meeting of the Japanese Breast Cancer Society, Presidential Symposium 2 , Yokohama, June 2007

Network construction to promote translational researches

Akemi Kataoka, Shinji Ohno, Masakazu Toi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Tatsuya Toyama, Norikazu Masuda, Eriko Tokunaga; Japan Breast Cancer Research Group (JBCRG)
The 15th annual meeting of the Japanese Breast Cancer Society, Yokohama, June 2007

JBCRG02: Study of FEC 100 followed by docetaxel 100 as preoperative chemotherapy in primary breast cancer

Tsuyoshi Hamaoka, Seigo Nakamura, Norikazu Masuda, Hiroji Iwata, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
The 15th annual meeting of the Japanese Breast Cancer Society, Yokohama, June 2007

Back to Page Top

2006(Apr., 2006~ Mar.,2007)

Significance of HER2 for predicting pathological complete response to preoperative treatment with FEC followed by docetaxel

Toi M, Nakamura S, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F;Japan Breast Cancer Research Group (JBCRG).
29th San Antonio Breast Cancer Symposium, Poster, San Antonio (USA), Dec. 2006

Premature ovarian disfunction induced by neopadjuvant chemotherapy (FEC followed by docetaxel) for breast cancer

Shinano Hitomi, Hamaoka Tsuyoshi, Nakamura Seigo, Toi Masakazu, Kuroi Katsumasa; Japan Breast Cancer Research Group (JBCRG).
3rd Organisation for Oncology and Translational Research, Hong Kong, Oral, Sep. 2006

Study of FEC followed by docetaxel 100 as preoperative chemotherapy in primary breast cancer - JBCRG02 -

Seigo Nakamura, Norikazu Masuda, Hiroji Iwata, Masakazu Toi, Katsumasa Kuroi, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG)
The 14th annual meeting of the Japanese Breast Cancer Society, Kanazawa, July 2006

Preoperative chemotherapy in primary breast cancer: How to define pCR: Our Challenge.

Katsumasa Kuroi, Seigo Nakamura, Masakazu Toi, Hiroji Iwata, Mikihiro Kusama, Norikazu Masuda, Eisei Shin, Shinji Ohno, Kosuke Yamazaki, Yuichi Takatsuka, Kazufumi Hisamatsu, Masahiro Kashiwaba, Yasuyuki Sato, Hiroshi Kaise, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group (JBCRG)
The 106th Annual Congress of Japan Surgical Society, Tokyo, March 2006

The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer.

Nakamura S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG)
5th European Breast Cancer Conference, Nice (France), Mar. 2006

Back to Page Top

2005(Apr., 2005~ Mar.,2006)

Feasibility and efficacy of phase II trial of sequential preoperative FEC 100 followed by Docetaxel 100 in primary operable breast cancer.

Nakamura S, Masuda N, Iwata H, Toi M, Kuroi K, Akiyama F; Japan Breast Cancer Research Group (JBCRG)
2nd Organisation for Oncology and Translational Research, Tokyo, Nov. 2005

Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer

Norikazu Masuda, Seigo Nakamura, Masakazu Toi, Hiroji Iwata, Shinji Ohno, Yuichi Takatsuka, Kazufumi Hisamatsu, Kosuke Yamazaki, Mikihiro Kusama, Hiroshi Kaise, Yasuyuki Sato, Masahiro Kashiwaba, Eisei Shin, Katsumasa Kuroi, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group(JBCRG)
The 13th annual meeting of the Japanese Breast Cancer Society, Kurashiki, June 2005

Back to Page Top

2004(Apr., 2004~ Mar.,2005)

The effect of Pathological Response of Multicenter phase II trial of sequential FEC followed by docetaxel in primary operable breast cancer – interim analysis -

Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
27th San Antonio Breast Cancer Symposium, Poster, SanAntonio (USA), Dec. 2004

Multiphase II trial of sequential FEC followed by docetaxel in primary operative breast cancer.

Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
1st Organisation for Oncology and Translational Research, Hong Kong, Oct. 2004

Unargued issues on the pathological assessment of response in primary sytemic therapy for breast cancer.

Kuroi K, Toi M, Takatsuka Y, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG).
1st Organisation for Oncology and Translational Research, Hong Kong, Oct. 2004

Review of the study of CEF followed by Docetaxel as preoperative chemotherapy in primary breast cancer

Hiroji Iwata, Seigo Nakamura, Masakazu Toi, Eisei Shin, Norikazu Masuda, Shinji Ohno, Yuichi Takatsuka, Kazufumi Hisamatsu, Kosuke Yamazaki, Mikihiro Kusama, Hiroshi Kaise, Yasuyuki Sato, Katsumasa Kuroi, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group (JBCRG)
The 12th annual meeting of the Japanese Breast Cancer Society, Kokura, June 2004

Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF - DOC) as preoperative chemotherapy in primary operable breast cancer.

Nakamura S, Ohno S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Hisamatsu K, Yamazaki K, Masuda N, Akiyama F; Japan Breast Cancer Research Group (JBCRG)
2004 American Society of Clinical Oncology, New Orleans (USA), Jun. 2004

Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF - DOC) as preoperative chemotherapy in primary operable breast cancer.

Kuroi K, Toi M, Takatsuka Y, Iwata H, Ohno S, Kusama M, Shin E, Hisamatsu K, Yamazaki K, Sato Y, Masuda N, Kaise H, Akiyama F, Nakamura S; Japan Breast Cancer Research Group (JBCRG)
15th International Congress on Anti Cancer Treatment, Paris (France), Feb. 2004

Back to Page Top

2003(Apr., 2003~ Mar.,2004)

Review of the study of CEF followed by Docetaxel as preoperative chemotherapy in primary breast cancer

Eisei Shin, Seigo Nakamura, Masakazu Toi, Yuichi Takatsuka, Yasuyuki Sato, Shinji Ohno, Hiroji Iwata, Mikihiro Kusama, Kazufumi Hisamatsu, Hiroshi Kaise, Kosuke Yamazaki, Katsumasa Kuroi, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG)
The 41th annual meeting of the Japan Society of Clinical Oncology, Sapporo, Oct. 2003

Review of the study of CEF followed by Docetaxel as preoperative chemotherapy in primary breast cancer

Katsumasa Kuroi, Masakazu Toi, Yuichi Takatsuka, Shinji Ohno, Hiroji Iwata, Mikihiro Kusama, Eisei Shin, Yasuyuki Sato, Kosuke Yamazaki, Kazufumi Hisamatsu, Futoshi Akiyama, Seigo Nakamura; Japan Breast Cancer Research Group (JBCRG)
The 11th annual meeting of the Japanese Breast Cancer Society, Niigata, June 2003

Back to Page Top